Clinical trial
A Post-Market Study to Evaluate Adverse Event Incidence Rates in Patients With…
NCT00293163 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00293163 |
|---|---|
| Title | A Post-Market Study to Evaluate Adverse Event Incidence Rates in Patients With Skin of Color Undergoing Correction of Nasolabial Folds With Hylaform, Hylaform Plus and Captique. |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Collaborators | Inamed Aesthetics Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Facial Wrinkles |
| Intervention type | Device |
| Interventions | Hylaform, Hylaform Plus (hylan B gel) |
| Enrollment | 120 |
| Start date | Feb 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Feb 17, 2006 |
| Last update posted | Mar 5, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: